Newsletter Signup x
T-cell acute lymphoblastic leukaemia (T-ALL) is an aggressive and hard to treat cancer. CAR-T cell therapy has done an incredible job in improving survival rates for some cancer types, but it has been difficult to develop a CAR-T cell therapy against T-ALL that doesn’t also result in dangerous side-effects. Dr Marc Mansour and his team hope to produce the first CAR T-cells that can safely treat T-ALL cells without harming healthy cells.
Exploiting a novel immunotherapy target for the treatment of T-cell acute lymphoblastic leukaemia (T-ALL)
Dr Marc Mansour
UCL Cancer Institute
London WC1E 6DD
14 September 2020
36 months
£249,324.87
Characterising and targeting treatment resistant cells in Acute Lymphoblastic Leukaemia following treatment
Acute lymphoblastic leukaemia (ALL) is the most common childhood cancer. Most children and young adults with ALL are treated
Read more